Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time
These growth stocks have the potential to dramatically outperform if you are willing to bear the risks.
These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026
As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens
SAN DIEGO , Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...
This under-the-radar biotech stock is setting up for a big 2026.
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity